Core Viewpoint - Shandong Xinde Technology Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange for a main board listing, aiming to expand its production capacity and enhance R&D in new vaccines and pet medications [2][4] Company Overview - Founded in 1999 and registered in Weifang, Shandong, Xinde Technology is a leading animal health company in China, focusing on the R&D, production, and sales of veterinary biological products, traditional Chinese veterinary medicine, chemical drug formulations, feed, and feed additives [2] - The company ranks 9th among domestic manufacturers in China's animal health market with a market share of approximately 1.4%, and is among the top three in the poultry veterinary biological products market [2] Financial Performance - For the years 2023, 2024, and the first nine months of 2025, the company's revenue was reported at 985 million yuan, 982 million yuan, and 877 million yuan respectively, with gross profit margins of 49.7%, 50.8%, and 55.3% [2] - Net profits for the same periods were 34.76 million yuan, 28.12 million yuan, and 55.67 million yuan [2] - Overseas revenue has seen significant growth, increasing from 12.2 million yuan in 2023 to 46.1 million yuan in the first nine months of 2025, with products entering markets such as Pakistan, Egypt, and Vietnam [2] Strategic Initiatives - The company plans to use the funds raised from the IPO primarily to expand its production base and capacity, enhance R&D investment in new vaccines and pet medications, and expand its domestic and international sales networks [4] - The controlling shareholder is Chairman and President Li Chaoyang, who holds 45.08% of the voting rights, with Sumitomo Corporation, a Fortune Global 500 company, as a strategic shareholder [4]

Group 1 - The core viewpoint of the article is that Shandong Xinde Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to become a leading player in the animal health sector with a comprehensive industry chain and global perspective [1][3][5] Group 2 - Xinde Technology has established itself as a leader in the animal health industry, ranking among the top three in the core segment of avian veterinary biological products and holding a dominant position in several high-barrier niche markets [3][4] - The company has a strong research and development (R&D) platform, employing advanced technologies such as full suspension cell culture for producing high-pathogenic avian influenza vaccines, and has a team of 189 R&D personnel with over 60% holding master's degrees or higher [4] Group 3 - Financial performance has been robust, with a reported revenue of 877 million yuan for the first nine months of 2025, representing a year-on-year growth of 25.2%, and a pre-tax profit increase exceeding 100% [5] - The company's global strategy has led to explosive growth in overseas business, with overseas revenue reaching 46.1 million yuan, a year-on-year increase of 123.8% [5] Group 4 - The funds raised from the Hong Kong listing will be used to enhance R&D capabilities, expand advanced production capacity, and deepen global expansion efforts, with the goal of becoming a globally influential leader in animal health [7]

Core Viewpoint - The report highlights significant growth in poultry vaccines and the potential for the pet segment, with a "buy" rating for the company [1][5]. Financial Performance - In H1 2025, the company achieved a net profit of 116 million yuan, a year-on-year increase of 57.12% [2]. - The total revenue for H1 2025 was 559 million yuan, reflecting a 15.79% increase compared to the previous year [2]. - The company's non-recurring net profit was 100 million yuan, up 50.79% year-on-year [2]. - The sales expense ratio and management expense ratio were 22.2% and 6.7%, respectively, down 5.6 percentage points and 2.5 percentage points year-on-year [2]. Product Performance - The animal health industry faced increased competition, particularly in the swine vaccine segment, which saw a revenue decline of 11.49% to 131 million yuan [3]. - Poultry vaccine revenue grew by 30.01% to 259 million yuan, driven by the new production base in Nanjing and a nearly 60% increase in high pathogenic avian influenza vaccine revenue [3]. - The revenue from pet-related products reached 10.07 million yuan, with significant growth in functional health products, which increased by 124.47% [4]. Market Strategy - The company is focusing on both offline and online marketing strategies for its pet products, achieving over threefold growth in online sales [4]. - Various marketing activities and partnerships with distributors are being utilized to promote key products like the cat trivalent inactivated vaccine [4]. Future Outlook - The company is projected to achieve revenues of 1.216 billion yuan, 1.414 billion yuan, and 1.596 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 16.6%, 16.3%, and 12.8% [5]. - Corresponding net profits are expected to be 181 million yuan, 234 million yuan, and 259 million yuan, with growth rates of 95.4%, 29.2%, and 10.5% [5].

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [6]. Core Insights - The company reported a revenue of 560 million yuan for the first half of 2025, representing a year-on-year increase of 15.8%, and a net profit attributable to shareholders of 120 million yuan, up 57.1% year-on-year [1]. - The growth in revenue is significantly driven by the poultry vaccine production capacity expansion and the performance of the pet product segment, which is gaining traction in the market [2][3]. - The company is actively enhancing strategic partnerships with large breeding groups to improve its market share in vaccines and chemical drugs, with innovative products contributing to revenue growth [2]. - The pet product segment is experiencing remarkable growth, with online sales increasing by over three times, reflecting the growing market for pet-related products [3]. Summary by Sections Financial Performance - In H1 2025, the biological products revenue reached 401 million yuan, a year-on-year increase of 13.17%. The revenue from poultry products grew by 30.01% to 259 million yuan, while pet products saw a 49.65% increase to 10 million yuan [1]. - The company expects net profits for 2025 to be 228 million yuan, with earnings per share (EPS) projected at 0.66 yuan, corresponding to a price-to-earnings (PE) ratio of 22 [4][5]. Market Trends - The pet industry is projected to grow significantly, with the market size expected to reach 404.2 billion yuan by 2027, driven by increasing consumer spending on pets [3]. - The company is focusing on both online and offline marketing strategies to promote its pet vaccines and related products, capitalizing on the growing trend of pet ownership [3]. Future Outlook - The company anticipates a recovery in demand for animal health products as the market enters a consumption peak in the second half of 2025, supported by strong genetic engineering capabilities and ongoing vaccine development [4].

Financial Performance - In Q1 2025, the company achieved a revenue of 8.22 billion yuan, representing a year-on-year growth of 20% [3] - The net profit attributable to shareholders was 1.16 billion yuan, with a year-on-year increase of 28.45% [3] - The non-recurring net profit reached 9.35 million yuan, showing a growth of 19.65% year-on-year [3] Business Strategy - The company is focusing on international brand strategy, marking its transition from a regional to a global brand [3] - A 56% stake acquisition in Zhongrui Supply Chain was completed, enhancing collaboration across core business segments [3] - The company is implementing a share repurchase plan, with a total repurchase amount of 120 million yuan as of March 31, 2025 [3] Product Development - The high pathogenic avian influenza vaccine generated 87 million yuan in revenue, a 16% increase year-on-year, while the Marek's vaccine revenue reached 26 million yuan, up 59% [4] - The company plans to launch new products, including a cat oral dewormer and various mRNA vaccines for pets, to enrich its product matrix [4][5] Market Expansion - The company has nearly 100% coverage of its top 100 customers in the traditional livestock sector and aims to deepen strategic cooperation with major clients [6][7] - The international strategy includes a dual circulation approach for product and technology, focusing on overseas market expansion and enhancing service capabilities [7] Impact of Tariffs - Export business accounts for approximately 3% of total revenue, indicating minimal direct impact from US-China tariffs [7] - The company is monitoring tariff policy changes to adjust its business layout and product strategies accordingly [7]